Sunday, April 29, 2012

Pistachio Intake May Endorse a Valuable Gut Environment

Eating pistachios can help adjust levels of potentially valuable bacteria in the gut, a finding that holds promise for supporting digestive health counsels a preliminary 16-person study. The research, presented as an abstract this week at the Experimental Biology conference, is the first study of pistachios and almonds and their modulating role on the gut microbiota composition.


"Gut microbiota, or the microbial environment in the gastrointestinal tract, provides ...

Friday, April 27, 2012

Re: FDA Approves Votrient for Advanced Soft Tissue Sarcoma...


In continuation of my update on Pazopanib..


U.S. Food and Drug Administration, approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.

Votrient is a pill that works by interfering with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive.


A rare cancer with many subtypes, soft tissue sarcoma occurs in about 10,000 cases annually in the United States. More than 20 subtypes of sarcoma were included in the clinical trial leading to approval of Votrient. The drug is not approved for patients with adipocytic soft tissue sarcoma and gastrointestinal stromal tumors.


"Soft tissue sarcomas are a diverse group of tumors and the approval of Votrient for this general class of tumors is the first in decades," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "Drug development for sarcomas has been especially challenging because of the limited number of patients and multiple subtypes of sarcomas."
The safety and effectiveness of Votrient was evaluated in a single clinical study in 369 patients with advanced soft tissue sarcoma who had received prior chemotherapy. Patients were randomly selected to receive Votrient or a placebo. The study was designed to measure the length of time a patient lived without the cancer progressing (progression-free survival). The disease did not progress for a median of 4.6 months for patients receiving Votrient, compared with 1.6 months for those receiving the placebo.

The most common side effects in Votrient-treated patients were fatigue, diarrhea, nausea, weight loss, high blood pressure, decreased appetite, vomiting, tumor and muscle pain, hair color changes, headache, a distorted sense of taste, shortness of breath, and skin discoloration.

Votrient carries a boxed warning alerting patients and health care professionals to the potential risk of liver damage (hepatotoxicity), which can be fatal. Patients should be monitored for liver function and treatment should be discontinued if liver function declines.


Thursday, April 26, 2012

Gabapentin drug helps people to quit cannabis..

We know that, Gabapentin (see structure; brand names FanatrexGabaroneGraliseNeurontinNupentin) is a pharmaceutical drug, specifically a GABA analogue. It was originally developed for the treatment of epilepsy, and currently is also used to relieve neuropathic pain

Now Scientists at The Scripps Research Institute have found clinical evidence that the drug gabapentin, currently on the market to treat neuropathic pain and epilepsy, helps people to quit smoking marijuana (cannabis). Unlike traditional addiction treatments, gabapentin targets stress systems in the brain that are activated by drug withdrawal.

In a 12-week trial of 50 treatment-seeking cannabis users, those who took gabapentin used less cannabis, experienced fewer withdrawal symptoms such as sleeplessness, and scored higher on tests of attention, impulse-control, and other cognitive skills, compared to patients who received a placebo. If these results are confirmed by ongoing larger trials, gabapentin could become the first FDA-approved pharmaceutical treatment for cannabis dependence.

"A lot of other drugs have been tested for their ability to decrease cannabis use and withdrawal, but this is the first to show these key effects in a controlled treatment study," said Barbara J. Mason, the Pearson Family Chair and Co-Director of the Pearson Center for Alcoholism and Addiction Research at Scripps Research. "The other nice thing about gabapentin is that it is already widely prescribed, so its safety is less likely to be an issue."
Ref : http://www.nature.com/npp/journal/vaop/ncurrent/full/npp201214a.html 

Tuesday, April 24, 2012

Forty-year-old Fourier transform mass spectrometry phasing problem solved

Forty-year-old Fourier transform mass spectrometry phasing problem solved: Scientists have developed a computation which simultaneously doubles the resolution, sensitivity and mass accuracy of Fourier Transform Mass Spectrometry (FTMS) at no extra cost.

Liquorice root found to contain anti-diabetic substance

Omega-3 fatty acids may help to reduce the physical harm caused by smoking

In continuation of my update on Omega-3-fatty acids...

Omega-3 fatty acids may help to reduce the physical harm caused by smoking: Omega-3 fatty acids may help to reduce the physical harm caused by smoking, according to a new study.

Monday, April 23, 2012

Experts share top 5 springtime fruits and vegetables that fight cancer

Experts share top 5 springtime fruits and vegetables that fight cancer: The price of springtime fruits and vegetables seems to increase each year. But when buyers break this expense down to cents, they realize stocking up on these cancer-fighting foods still makes economical sense, say experts from The University of Texas MD Anderson Cancer Center.

Sunday, April 22, 2012

EMA CHMP recommends approval of AMAG’s ferumoxytol

EMA CHMP recommends approval of AMAG’s ferumoxytol: AMAG Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of ferumoxytol, an intravenous (IV) iron therapy, for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

More info on Ferumoxytol : http://www.druginformation.com/RxDrugs/F/Ferumoxytol%20Injection.html

Tuesday, April 17, 2012

Consumption of long-chain omega-3 PUFAs lowers risk of colorectal polyps in women


In continuation of my update on omega fatty acids
Consumption of long-chain omega-3 PUFAs lowers risk of colorectal polyps in women: New research finds that omega-3 polyunsaturated fatty acids (PUFAs) found in seafood (long-chain omega-3s) may reduce the risk of precancerous colorectal polyps in women, enhance the muscular benefits of strength training in older women and improve eye health after corneal surgery.

Monday, April 16, 2012

Natural products isolated from marine mollusks and sponges can reverse multidrug resistance in cancer cells


Oceans are a treasure trove of naturally produced chemical compounds with impressive and varied biological activity. One class of these compounds, the lamellarins, has some members that are cytotoxic, while others are able to reverse multidrug resistance in certain cancer cells. These lamellarins (see below structure) act by inhibiting the so-called P-glycoprotein, which enhances transport of anticancer agents out of cancer cells, thus rendering the cells multidrug resistant.

Now researchers lead by Professor Rob Capon, have set out to determine the structures of a variety of lamellarins and correlate them to the activity of the compounds. As they report in Chemistry—An Asian Journal, the activity is not determined by the core structure of the compounds but rather depends on the exact nature of pendant groups adorning the periphery of the molecule. Those compounds in which many hydroxy (OH) groups had been replaced with methoxy (OCH3) were able to reverse multidrug resistance in human colon cancer cells, while those featuring a large number of hydroxy groups showed higher cytotoxic activity.

Natural products such as the lamellarins are often valued for their cytotoxic properties for use as anticancer drugs. Capon, however, comments, "Our investigation reaffirms the view that non-cytotoxic natural products can exhibit valuable biological properties that allude to both an ecological advantage and a pharmacological potential....

Sunday, April 15, 2012

Coffee's Unique Health Benefits........

In continuation of my update on coffee
 
  • Coffee is the greatest source of antioxidants in the American diet.3,4 And the good news is that sound scientific studies have found that the common fears about excess coffee consumption are invalid, and higher intake means bigger benefits. 
  • An impressive number of studies have shown a strong association between higher consumption of coffee and a significantly reduced risk of most chronic diseases, including diabetes, cardiovascular disease, cancer, Alzheimer's disease, and others.
  • With over 1,000 phytochemicals, coffee's unparalleled antioxidant punch no doubt plays a role in its protection against disease. But a multitude of direct biological actions on the body are suspected, such as an improvement in intracellular signaling,95,96 which may help prevent cancer, diabetes and more.
  • Drinking just one cup of coffee a day - caffeinated or decaffeinated - can decrease the risk of developing diabetes by 13%.24 But at 12 cups a day, the risk of getting diabetes is slashed by 67%.21
  • Far from being a risky habit, coffee has now been shown to provide powerful protection against an epidemic of diabetes and a rising tide of other age-related diseases. It's an all-natural and inexpensive elixir - to go!
 While I wanted to compile all the benefits of coffee in one article, I found a detailed article and many interesting ones at  Life Extension Magazine.  


Neupro Approved by U.S. FDA for Parkinson's Disease and Restless Legs Syndrome

 We know that, Rotigotine (see below structure, Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.

 
Neupro Approved by U.S. FDA for Parkinson's Disease and Restless Legs Syndrome:  UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic...

Saturday, April 14, 2012

Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia

 In continuation of my update on Liraglutide

Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia:  Novo Nordisk received approval from the U.S. Food and Drug Administration (FDA) to update the product label for Victoza (liraglutide [rDNA origin] injection) to include data showing superior blood...